Kontochristopoulos Georgios, Tsiogka Aikaterini, Agiasofitou Efthymia, Kapsiocha Anastasia, Soulaidopoulos Stergios, Liakou Aikaterini I, Gregoriou Stamatios, Rigopoulos Dimitrios
First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Syggros Hospital, Athens, Greece.
First Department of Cardiology, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Skin Appendage Disord. 2022 Nov;8(6):476-481. doi: 10.1159/000524762. Epub 2022 May 13.
Antibiotics are frequently used to treat hidradenitis suppurativa (HS), but the evidence-based literature available on their use is limited. Considering that HS is not primarily an infectious disease, we sought to evaluate the efficacy of subantimicrobial, modified-release doxycycline (MR-DC) compared to regular-release doxycycline (RR-DC) for the treatment of HS.
Patients were randomly assigned to receive treatment with either MR-DC 40 mg once daily or RR-DC 100 mg twice daily for a period of 12 weeks. The treatment efficacy was assessed after 12 weeks of treatment using the International Hidradenitis Suppurativa Severity Score System (IHS4), the Dermatology Life Quality Index (DLQI), and the Hidradenitis Suppurativa Clinical Response (HiSCR).
A total of 49 patients (25 in the MR-DC group and 24 in the RR-DC group) were included in the study. A statistically significant ( < 0.05) reduction of IHS4 and DLQI was observed in both groups at week 12. HiSCR was achieved by 64% of patients receiving MR-DC and 60% of those receiving RR-DC.
MR-DC demonstrated comparable efficacy to RR-DC in the treatment of HS. MR-DC may serve as a valuable alternative to other antibiotic regimes, considering its anti-inflammatory properties and its lower potential to induce antibiotic resistance.
抗生素常用于治疗化脓性汗腺炎（HS），但其使用的循证文献有限。鉴于HS并非主要的传染病，我们试图评估亚抗菌、缓释强力霉素（MR-DC）与常规释放强力霉素（RR-DC）相比治疗HS的疗效。
患者被随机分配接受治疗，一组每天一次服用40毫克MR-DC，另一组每天两次服用100毫克RR-DC，为期12周。治疗12周后，使用国际化脓性汗腺炎严重程度评分系统（IHS4）、皮肤病生活质量指数（DLQI）和化脓性汗腺炎临床反应（HiSCR）评估治疗效果。
共有49名患者（MR-DC组25名，RR-DC组24名）纳入研究。在第12周时，两组的IHS4和DLQI均有统计学显著降低（<0.05）。接受MR-DC治疗的患者中有64%达到HiSCR，接受RR-DC治疗的患者中有60%达到HiSCR。
MR-DC在治疗HS方面显示出与RR-DC相当的疗效。考虑到其抗炎特性和较低的诱导抗生素耐药性的可能性，MR-DC可能是其他抗生素治疗方案的有价值替代方案。
